Advanced Cell and Gene Therapy (CGT) Tools
The rapid commercialization of cell and gene therapies in 2026 has created a massive demand for specialized manufacturing and quality control tools.
In Vivo Gene Editing: Tools like CRISPR-Cas9 have moved from the lab to clinical use, requiring high-precision delivery systems (like lipid nanoparticles) and specialized verification kits.
Single-Use Bioreactors: Modular, plastic-based bioreactors that allow for flexible, sterile production of cell therapies, reducing the risk of cross-contamination.
Quality Control (QC) Automation: Systems that provide real-time testing of cell viability and purity during the manufacturing process, rather than waiting for post-production results.
3 Views